Results 231 to 240 of about 28,764 (283)
Some of the next articles are maybe not open access.
Endocrinology and Metabolism Clinics of North America, 1997
Sulfonylureas have been available for the treatment of non-insulin-dependent diabetes mellitus (NIDDM) since the 1950s. With the introduction of new oral agents, there is a tendency to discount the value of sulfonylurea therapy. Sulfonylureas have the advantage of multiple formulations, low costs, minimal side effects, and demonstrated efficacy in ...
openaire +2 more sources
Sulfonylureas have been available for the treatment of non-insulin-dependent diabetes mellitus (NIDDM) since the 1950s. With the introduction of new oral agents, there is a tendency to discount the value of sulfonylurea therapy. Sulfonylureas have the advantage of multiple formulations, low costs, minimal side effects, and demonstrated efficacy in ...
openaire +2 more sources
Diabetes Care, 1992
Sulfonylureas have represented the backbone of oral therapy in non-insulin-dependent diabetes mellitus for > 30 yr. Despite this, our knowledge about the mode of actions of these agents is limited, and the use of them is far from rational. Sulfonylureas lower blood glucose concentrations primarily by stimulating insulin secretion.
openaire +2 more sources
Sulfonylureas have represented the backbone of oral therapy in non-insulin-dependent diabetes mellitus for > 30 yr. Despite this, our knowledge about the mode of actions of these agents is limited, and the use of them is far from rational. Sulfonylureas lower blood glucose concentrations primarily by stimulating insulin secretion.
openaire +2 more sources
Potential Hypoglycemic Sulfonylureas
Journal of Pharmaceutical Sciences, 1964A series of N ′-alkyl- N - p -phenylbenzenesulfonylureas and N , N ′-bis ( N -alkylcarbamyl) 4,4′-biphenyldisulfonamides has been prepared for pharmacological studies of their hypoglycemic activities.
K A, NIEFORTH, G L, JENKINS, A M, KNEVEL
openaire +2 more sources
Acta medica portuguesa, 1990
Oral antidiabetics are an important aspect of treatment in many diabetics and in the last few years with new developments in the knowledge of type II diabetes physiopathology, there has been a lot of interest in their actions mechanisms. Oral therapy is nevertheless a mere complement which needs to be fitted into a wider group of measures: diabetics ...
openaire +3 more sources
Oral antidiabetics are an important aspect of treatment in many diabetics and in the last few years with new developments in the knowledge of type II diabetes physiopathology, there has been a lot of interest in their actions mechanisms. Oral therapy is nevertheless a mere complement which needs to be fitted into a wider group of measures: diabetics ...
openaire +3 more sources
Sulfonylureas have been a mainstay in the pharmacologic treatment of T2D for over 60 years. The first-generation sulfonylureas (e.g., chlorpropamide, tolbutamide, and tolazamide) are no longer available in the United States. With the availability of many noninsulin classes of medications for T2D, sulfonylurea usage is on the decline, yet their use ...
Elmo M. Beyer +3 more
openaire +2 more sources
Elmo M. Beyer +3 more
openaire +2 more sources
Hepatic effect of sulfonylureas
Metabolism, 1970Abstract The sulfonylureas, tolbutamide, tolazamide and acetohexamide significantly diminish uptake of insulin by the isolated perfused rat liver, whereas the nonhypoglycemic metabolite of tolbutamide, carboxytolbutamide, has no such effect. These results suggest that the sustained action of the sulfonylureas may in part be due to reduced hepatic ...
A, Marshall, R L, Gingerich, P H, Wright
openaire +2 more sources
Postgraduate Medicine, 1992
The clinical use of sulfonylureas described in this article is both rational and effective for diabetic patients. Sulfonylureas are not used (1) in patients with insulin-dependent (type I) diabetes, because they are completely ineffective or (2) in patients with non-insulin-dependent (type II) diabetes who respond satisfactorily to diet, because they ...
openaire +2 more sources
The clinical use of sulfonylureas described in this article is both rational and effective for diabetic patients. Sulfonylureas are not used (1) in patients with insulin-dependent (type I) diabetes, because they are completely ineffective or (2) in patients with non-insulin-dependent (type II) diabetes who respond satisfactorily to diet, because they ...
openaire +2 more sources
Clinical pharmacology of sulfonylureas
Metabolism, 1987Sulfonylureas seem to have similar mechanisms of action, including an acceleration and increase of insulin secretion, an increase of the systemic availability of insulin, and probably indirectly, an increase of insulin action. Sulfonylureas may postpone the development of impaired glucose tolerance (IGT) to manifest non-insulin-dependent diabetes ...
openaire +2 more sources
Hyperlipemia and Sulfonylurea Therapy
JAMA, 1964To the Editor:— A report by Shipp et al ( JAMA 188: 468 [May 4] 1964), describing severe hyperlipemia in three diabetics treated with sulfonylurea compounds, proposes that "... enough control to prevent ketosis, but not enough to prevent hyperglycemia, may have provided a longterm metabolic balance favoring the development of hyperlipemia." It is ...
openaire +2 more sources
Sulfonylurea Signal Transduction
1991In the pancreatic beta cells the proximal step in sulfonylurea signal transduction is the binding of these clinically important drugs to high-affinity receptors in the beta cell membrane. Using HIT cells as a model system, we have established an extremely close correlation between the affinity of binding of glyburide and its analog, iodoglyburide, and ...
A E, Boyd +9 more
openaire +2 more sources

